Trial · NCT05759312
Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma
NCT05759312, Phase 1, Phase 2, Unknown, Fudan University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma. Trials, record NCT05759312. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05759312
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma
- NCT number
- NCT05759312
- Status
- Unknown
- Phases
- Phase 1, Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Fudan University
- Conditions
- Ovarian Clear Cell Carcinoma
- Interventions
- Zimberelimab, Metformin Hydrochloride
- First posted
- 2023-03-08
- Last updated
- 2023-03-08
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Objective response rate | Up to 2 years | The proportion of patients with complete response (CR) and partial response (PR) assessed by the investigator in accordance with the RECIST 1.1 criteria |
| Secondary | Progression-free survival | Up to 2 years | The time from entry into the study to the diagnosis of the first progression or recurrence or death, whichever occurs first |
| Secondary | Overall survival | Up to 2 years | The time from date of randomization until the date of death from any cause or last follow-up |
| Secondary | Disease control rate | Up to 2 years | The proportion of patients who achieved complete response (CR) or partial response (PR) or stable disease (SD) assessed by the investigator in accordance with the RECIST 1.1 criteria |
| Secondary | Duration of response | Up to 2 years | The time interval from the first record of disease response to disease progression or death (whichever occurs first) |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 | Up to 2 years | The adverse event assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 |
| Secondary | Patterns of subsequent recurrence | Up to 2 years | The number and sites of subsequent recurrence, including pelvic, abdominal, retroperitoneal lymph nodes, hepato-celiac lymph nodes and distant metastases and ascites, etc.) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05759312
GET https://conductscience.org/api/trials/v1/NCT05759312/registered